Istanbul University Institute of Health Sciences Journal of Advanced Research in Health Sciences, vol.3, no.3, pp.186-194, 2020 (Peer-Reviewed Journal)
Objective: The neutrophil-to-lymphocyte ratio(NLR) is a biomarker for systematic inflammation.
It is also thought that the NLR can be used as a new biomarker by clinicians in predicting the
prognosis of patients with multiple myeloma(MM). This study, aimed to retrospectively investigate
the prognostic significance of pretreatment NLR in patients with MM, based on the hypothesis
that elevated pretreatment NLR is a biomarker indicating worse survival in patients with MM.
Materials and Methods: Patients aged >18 years with MM diagnosed, follow-up, and treated
between January 2011 and December 2017 in the department of internal and geriatric
medicine at Istanbul Faculty of Medicine were enrolled into this study. We retrospectively
collected the data of 40 patients from the medical records. The relationship between NLR and
baseline characteristics, laboratory parameters, prognosis, and survival outcome was analyzed.
Results: The study showed that the mean NLR was 2.84±2.62 (0.1-14.8) in the whole blood
count. No significant correlation was found between NLR and mortality (p=0.965). A
significant relationship was found between higher stage and mortality (p=0.035). In addition,
anemia, low albumin level, and elevated lactate dehydrogenas (LDH) level indicated poor
survival time in patients with MM (p=0.022; p=0.031; p=0.023).
Conclusion: Our study showed no relationship between NLR and both mortality and overall
survival (OS). The above result can be explained by the fact that our study had some limitations
such as the use of retrospective data from a single-center and the small sample size.
Keywords: Multiple myeloma, neutrophil-lymphocyte ratio, overall survival